An Adaptive Transfer-Learning-Based Deep Cox Neural Network for Hepatocellular Carcinoma Prognosis Prediction
Source check: Source checked. Not independent scientific confirmation.
Finding: TCGA training and three independent GEO tests support robustness; the study identifies markers including TTC36 and reports cell experiments. Independent datasets and cell assays support the study-specific result, not treatment efficacy or prospective patient benefit.
Technology: An adaptive transfer-learning deep Cox network selects pretraining cancer types and predicts hepatocellular-carcinoma survival from expression data.
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- An adaptive transfer-learning deep Cox network selects pretraining cancer types and predicts hepatocellular-carcinoma survival from expression data.
- Test and result
- TCGA training and three independent GEO tests support robustness; the study identifies markers including TTC36 and reports cell experiments.
- Limitation / still unknown
- Independent datasets and cell assays support the study-specific result, not treatment efficacy or prospective patient benefit.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.692774/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.